Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme

References

• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16:iv1–i63.
   PubMed Web of Science ®Google Scholar
• Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials. 2009;30:2302–2318.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Gilbert MR, et al. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 2007;25:4127–4136.
   PubMed Web of Science ®Google Scholar
• Kawano H, Hirano H, Yonezawa H, et al. Improvement in treatment results of glioblastoma over the last three decades and beneficial factors. Br J Neurosurg. 2015;29:206–212.
   PubMed Web of Science ®Google Scholar
• Verhaak RGW, Hoadley KA, Purdom E, et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell. 2010;17:98.
   PubMed Web of Science ®Google Scholar
• Nehoff H, Parayath NN, McConnell MJ, et al. A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme. Oncotarget. 2015;6:37948–37964.
   PubMed Web of Science ®Google Scholar
• Vandyke K, Fitter S, Zannettino AC. The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer J. 2011;1:e2.
   PubMed Web of Science ®Google Scholar
• Kong DS, Song SY, Kim DH, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009;115:140–148.
   PubMed Web of Science ®Google Scholar
• Tajes M, Ramos-Fernandez E, Weng-Jiang X, et al. The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol Membr Biol. 2014;31:152–167.
   PubMed Web of Science ®Google Scholar
• Levin VA, Tonge PJ, Gallo JM, et al. CNS anticancer drug discovery and development conference white paper. Neuro Oncol. 2015;17(6):vi1–v26.
   Web of Science ®Google Scholar
• Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J Control Release. 2012;164:265–275.
   PubMed Web of Science ®Google Scholar
• Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond). 2010;5:523–528.
   PubMed Web of Science ®Google Scholar
• Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112–1116.
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Kramer CM, Sodickson DK, et al. Meeting highlights of the 10th annual scientific sessions of the society for cardiovascular magnetic resonance and 6th annual meeting of the working group for cardiovascular magnetic resonance of the European society of cardiology. J Am Coll Cardiol. 2007;50:983–987.
   PubMed Web of Science ®Google Scholar
• Taurin S, Allen KM, Scandlyn MJ, et al. Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression. Int J Oncol. 2013;43:785–792.
   PubMed Web of Science ®Google Scholar
• Walker JM. The bicinchoninic acid (BCA) assay for protein quantitation. Methods Mol Biol. 1994;32:5–8.
   PubMedGoogle Scholar
• Fukumura D, Xu L, Chen Y, et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 2001;61:6020–6024.
   PubMed Web of Science ®Google Scholar
• Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011;108:3749–3754.
   PubMed Web of Science ®Google Scholar
• MEA. SPRYCEL. In.; 2006. p. 1–46. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000709/WC500056995.pdf
   Google Scholar
• Lassman AB, Pugh SL, Gilbert MR, et al. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol. 2015;17:992–998.
   PubMed Web of Science ®Google Scholar
• Franceschi E, Stupp R, van den Bent MJ, et al. EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro Oncol. 2012;14:1503–1510.
   PubMed Web of Science ®Google Scholar
• Taylor JW, Dietrich J, Gerstner ER, et al. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015;121:557–563.
   PubMed Web of Science ®Google Scholar
• Reardon D, Desjardins A, Vredenburgh J, et al. A phase I trial of dasatinib (Sprycel) and erlotinib (Tarceva) for patients with recurrent malignant glioma. Neuro Oncol. 2008;840–840. (suppl; abstr 2032) [meeting abstract].
   Google Scholar
• Laack NN, Galanis E, Leinweber C, et al. Phase I/randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): final results of phase I study. J Clin Oncol. 2012;30:2032.
   Web of Science ®Google Scholar
• Kato S, Jardim DLF, Johnson FM, et al. Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer. J Clin Oncol. 2015;33:2597–2597.
   PubMed Web of Science ®Google Scholar
• Furmanski BD, Hu S, Fujita K, et al. Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. Clin Cancer Res. 2013;19:4359–4370.
   PubMed Web of Science ®Google Scholar
• Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008;36:1357–1364.
   PubMed Web of Science ®Google Scholar
• Greish K, Sawa T, Fang J, et al. SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. J Control Release. 2004;97:219–230.
   PubMed Web of Science ®Google Scholar
• Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res. 2008;14:3881–3888.
   PubMed Web of Science ®Google Scholar
• Nehoff H, Parayath N, Taurin S, et al. The influence of drug loading on caveolin-1 mediated intracellular internalization of doxorubicin nanomicelles in vitro. J Nanomed Nanotechnol. 2014;5:197.
   Google Scholar
• Parat MO, Riggins GJ. Caveolin-1, caveolae, and glioblastoma. Neurooncology. 2012;14:679–688.
   PubMed Web of Science ®Google Scholar
• Premkumar DR, Jane EP, Agostino NR, et al. Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells. J Carcinog. 2010;9:7.
   PubMedGoogle Scholar
• Millar AW, Lynch KP. Rethinking clinical trials for cytostatic drugs. Nat Rev Cancer. 2003;3:540–545.
   PubMed Web of Science ®Google Scholar
• Eisele GnWeller M. Targeting apoptosis pathways in glioblastoma. Cancer Lett. 2013;332:335–345.
   PubMed Web of Science ®Google Scholar
• Stegh AH, Brennan C, Mahoney JA, et al. Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev. 2010;24:2194–2204.
   PubMed Web of Science ®Google Scholar
• Saad S, Wang TJ. Neurocognitive deficits after radiation therapy for brain malignancies. Am J Clin Oncol. 2014;38:634–640.
   Web of Science ®Google Scholar
• Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys. 1980;6:1215–1228.
   PubMed Web of Science ®Google Scholar
• Burger PC, Mahley MS Jr, Dudka L, et al. The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases. Cancer. 1979;44:1256–1272.
   PubMed Web of Science ®Google Scholar
• Edwards JG, Swinson DE, Jones JL, et al. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest. 2003;124:1916–1923.
   PubMed Web of Science ®Google Scholar
• Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641–648.
   PubMed Web of Science ®Google Scholar
• Leek RD, Landers RJ, Harris AL, et al. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer. 1999;79:991–995.
   PubMed Web of Science ®Google Scholar
• Chen Y, Jing Z, Luo C, et al. Vasculogenic mimicry-potential target for glioblastoma therapy: an in vitro and in vivo study. Med Oncol. 2012;29:324–331.
   PubMed Web of Science ®Google Scholar
• El Hallani S, Boisselier B, Peglion F, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain. 2009;133:973–982.
   Web of Science ®Google Scholar
• Renner DN, Jin F, Litterman AJ, et al. Effective treatment of established GL261 murine gliomas through picornavirus vaccination-enhanced tumor antigen-specific CD8+ T cell responses. PLoS One. 2015;10:e0125565.
   PubMed Web of Science ®Google Scholar
• Jacobs VL, Valdes PA, Hickey WF, et al. Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro. 2011;3:e00063.
   PubMed Web of Science ®Google Scholar
• Noell S, Ritz R, Wolburg-Buchholz K, et al. An allograft glioma model reveals the dependence of aquaporin-4 expression on the brain microenvironment. PLoS One. 2012;7:e36555.
   PubMed Web of Science ®Google Scholar
• Takano S, Yamashita T, Ohneda O. Molecular therapeutic targets for glioma angiogenesis. J Oncol. 2010;2010:11.
   Google Scholar
• Dvorak HF. Rous-whipple award lecture. How tumors make bad blood vessels and stroma. Am J Pathol. 2003;162:1747–1757.
   PubMed Web of Science ®Google Scholar